The round is led by Mubadala Capital and Exor Ventures, with Qatar Investment Authority, Abingworth and 4 others participating.
Iambic Therapeutics Issuer · Mubadala Capital Lead investor · Exor Ventures Lead investor · Qatar Investment Authority Investor · Abingworth Investor · Illumina Ventures Investor · Nexus Venture Partners Investor · Coatue Investor · Tao Capital Partners Investor
As of this development: a later development may record new terms.
Four of eight investors were in an earlier Iambic Therapeutics round.
| Date | Round | Amount | Post-money | Led by | Returning |
|---|---|---|---|---|---|
| 10 November 2025 | Funding round | at least $100M | — | — | 6 of 16 |
| 18 June 2024 | Series B extension | $50M | — | Mubadala Capital, Exor Ventures | 4 of 8 |
| 3 October 2023 | Series B | $100M | — | Ascenta Capital, Abingworth | 0 of 13 |
Listed
Minutes shows stakes only when a party discloses them.
Iambic Therapeutics Issuer
Mubadala Capital Lead investor
Exor Ventures Lead investor
Qatar Investment Authority Investor